Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by Citigroup

Vor Biopharma (NASDAQ:VOR) was upgraded by Citigroup to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Several other research analysts have also issued reports on VOR. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Wedbush raised their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR traded down $1.31 during trading hours on Thursday, reaching $18.03. The stock had a trading volume of 733,078 shares, compared to its average volume of 1,316,671. Vor Biopharma has a twelve month low of $6.50 and a twelve month high of $31.31. The business’s fifty day moving average is $21.57 and its two-hundred day moving average is $18.37.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Sell-side analysts expect that Vor Biopharma will post -2.56 EPS for the current year.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cannon Global Investment Management LLC bought a new stake in shares of Vor Biopharma during the 1st quarter worth about $209,000. Sei Investments Co. acquired a new stake in Vor Biopharma during the first quarter worth approximately $245,000. Independent Financial Group LLC acquired a new stake in Vor Biopharma during the first quarter worth approximately $249,000. Wellington Management Group LLP bought a new stake in shares of Vor Biopharma during the second quarter worth approximately $499,000. Finally, Irenic Capital Management LP acquired a new position in shares of Vor Biopharma in the first quarter valued at approximately $583,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.